REMARKS

The specification has been amended to provide a crossreference to the previously filed International Application.

The claims have been amended to delete improper multiple dependencies and to place the application into better form for examination. An Abstract has been added to due to its being omitted during translation of the International Application.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

Jr.,

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

Attachment:

1110-0305P

GMM/cqc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The claims have been amended as follows:

- 4. (Amended) A composition for disintegration in lower gastrointestinal tract according to [any one of claims 1 to 3] claim 1, characterized in that the compound A> is any compound optionally selected from the group consisting of L-cystine, D-cystine, DL-cystine, diglycyl cystine, cystamine, L-cystinyldiglycine, glutathione disulfide, and thioglycolic acid disulfide (HOOC-R-S-S-R-COOH/R represents a lower alkylene group).
- 5. (Amended) A composition for disintegration in lower gastrointestinal tract according to [any one of claims 1 to 4] claim 1, characterized in that the polymer is any polymer optionally selected from the group consisting of chitosan, dimethylaminoethyl methacrylate/methyl methacrylate/butyl methacrylate copolymer, polyvinyl acetal diethylaminoacetate or mixtures thereof.
- 6. (Amended) A composition for disintegration in lower gastrointestinal tract according to [any one of cliams 1 to 5] claim 1, characterized in that the compound <A> is cystine and the polymer is at least chitosan.

- 7. (Amended) A composition for disintegration in lower gastrointestinal tract according to [any one of claims 3 to 6] claim 3, characterized in that the substance that controls disintegration rate at the lower gastrointestinal tract is at least one substance that controls disintegration rate at the lower gastrointestinal tract optionally selected from the group consisting of ethylcellulose, agar, pectin metal carrageenin, qelatin, pectin, starch, cellulose, dimethylaminoethyl
- methacrylate/methylmethacrylate/butylmethacrylate copolymer and polyvinylacetal diethylaminoacetate.
- 8. (Amended) A formed product for releasing an active ingredient <C> in lower gastrointestinal tract, comprising a formed product of the composition according to [any one of claims 1 to 7] claim 1.
- 11. (Amended) preparation for Α release in lower gastrointestinal tract, characterized in that an active ingredient <C> and the composition for disintegration in lower gastrointestinal tract according to [any one of claims 1 to 7] claim 1 are coated with an enteric polymer film.
- 12. (Amended) A preparation for release in lower gastrointestinal tract according to claim 11, characterized in that a composition containing an active ingredient <C> and

Docket No. 1110-0305P

pharmaceutically acceptable carrier is coated with the composition for disintegration in lower gastrointestinal tract according to [any one of claims 1 to 7] claim 1 and further coated with an enteric polymer film.

- 13. (Amended) A system for peroral uptake of a material desired to be delivered to lower gastrointestinal tract and selective release in the lower gastrointestinal tract, characterized in that the composition for disintegration in lower gastrointestinal tract according to [any one of claims 1 to 7] claim 1 and an enteric polymer film are used.
- 14. (Amended) A system for peroral of a material desired to be delivered to lower gastrointestinal tract and selective release in the lower gastrointestinal tract according to claim 13, characterized in that the material desired to be delivered to the lower gastrointestinal tract is coated with or added to the composition for disintegration in the lower gastrointestinal tract according to [any one of claims 1 to 7] claim 1, and further coated with an enteric polymer film.

(Rev. 11/13/01)